ClinicalTrials.gg
Status unknownNCT00002318Updated Jun 24, 2005

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

A Phase 3 interventional study of Doxorubicin hydrochloride (liposomal) and Bleomycin sulfate in Sarcoma, Kaposi and HIV Infections, sponsored by Sequus Pharmaceuticals. Status unknown at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Sequus Pharmaceuticals · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 1996), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Sarcoma, Kaposi with a site in United States — 13 open to participants now, 18 under way, none of them phase 3. Sarcoma, Kaposi · United States.

Enrollment
3rd of 82
225 · median 31
Phase 3
7 of 115
none open now
Registered
6th of 115
by date
Lead sponsor
4 of 115
Sequus Pharmaceuticals

Among the 115 studies in Sarcoma, Kaposi with a site in United States, this one is the 3rd largest by enrollment of the 82 interventional ones that give a count, is one of 7 in phase 3, and was the 6th registered.

Sarcoma, Kaposi

161 studies on the registry are indexed under Sarcoma, Kaposi; 24 are open to participants now.

Browse Sarcoma, Kaposi studies →

Open to participants now

13 of the 115 studies in Sarcoma, Kaposi with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Sarcoma, Kaposi studies recruiting now, 11 (52%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Sarcoma, Kaposi with a site in United States, or all of them as a file.
02

Study summary

To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy ABV: Adriamycin (doxorubicin)/bleomycin/vincristine. To evaluate the safety and tolerance of DOX-SL compared to ABV in a population of AIDS patients with severe KS.

Read the detailed description

Patients are randomized to receive either DOX-SL or the ABV combination. Infusions are given on day 1 and every 2 weeks for a total of six cycles. Kaposi's sarcoma lesions are evaluated prior to every cycle, at the end of the last treatment cycle, and 4 weeks following the end of the last treatment. Patients must agree to have one or more representative KS lesions biopsied.

03

Conditions studied

  • Sarcoma, Kaposi
  • HIV Infections

Keywords

  • Vincristine
  • Sarcoma, Kaposi
  • Liposomes
  • Doxorubicin
  • Drug Therapy, Combination
  • Acquired Immunodeficiency Syndrome
  • Bleomycin
  • Drug Carriers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Concurrent Medication:

Allowed:

  • Prophylaxis for PCP, cryptococcal, and herpes infections, and antiretroviral therapy (e.g., AZT, ddC, ddI) provided these doses have been stable for at least 1 month.
  • Therapy for tuberculosis, fungal, and herpes infections except with potentially myelotoxic chemotherapy.
  • Foscarnet for new episodes of cytomegalovirus infection.
  • Colony-stimulating factors and erythropoietin.

Patients must have:

  • -proven, progressive, AIDS-related Kaposi's sarcoma, with any of the following:
  • At least 25 mucocutaneous lesions.
  • Ten or more new lesions in the prior month.
  • Documented visceral disease with at least two accessible cutaneous lesions.
  • Two accessible cutaneous lesions with edema.
  • Documented anti- antibody.
  • No active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii, or other microorganisms (if under treatment with myelotoxic drugs).
  • > 4 months.

NOTE:

  • Patients who respond to therapy on this protocol, as well as those who fail the ABV combination, are eligible to enter the Liposome Technology open trial using DOX-SL alone.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • cardiac, hepatic, or renal disease.
  • Peripheral neuropathy, signs of moderate to severe sensory loss, or moderate to marked motor loss.
  • Inability to comply with the study.

Concurrent Medication:

Excluded:

  • Other cytotoxic chemotherapy.
  • Ganciclovir.

Patients with the following prior conditions are excluded:

  • Prior neoplasms treated with extensive chemotherapy that, in the investigator's opinion, has led to irreversibly compromised bone marrow function.
  • History of idiosyncratic or allergic reaction to bleomycin or vincristine.

Prior Medication:

Excluded:

  • Prior anthracycline therapy.
  • Cytotoxic chemotherapy or interferon treatment within the past 4 weeks.

Prior Treatment:

Excluded:

  • Radiation or electron beam therapy within the past 3 weeks.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
225 participants
06

Study locations

28 sites
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • Pacific Oaks Med Group
    Beverly Hills, California 90211, United States
  • Hematology - Oncology Med Group of San Fernando Valley
    Encino, California 91436, United States
  • Dr Becky Miller
    Los Angeles, California 90048, United States
  • Apogee Med Group
    San Diego, California 92103, United States
  • UCSF - San Francisco Gen Hosp
    San Francisco, California 94110, United States
  • Kaiser Permanente Med Ctr
    San Francisco, California 94115, United States
  • UCSF
    San Francisco, California 94117, United States
  • San Francisco Veterans Administration Med Ctr
    San Francisco, California 94121, United States
  • UCSF
    San Francisco, California 941430324, United States
  • Pacific Oaks Med Group
    Sherman Oaks, California 91403, United States
  • Dr Mahmoud Mustafa
    Washington, District of Columbia 20037, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • H Lee Moffit Cancer Ctr and Research Institute
    Tampa, Florida 33612, United States
  • American Med Research Institute
    Atlanta, Georgia 30329, United States
  • Infectious Disease Rsch Consortium of GA / SE Clin Resources
    Atlanta, Georgia 30345, United States
  • Northwestern Med Faculty Foundation
    Chicago, Illinois 60611, United States
  • Rush Presbyterian Med College
    Chicago, Illinois 60612, United States
  • Illinois Masonic Med Ctr / The Cancer Ctr
    Chicago, Illinois 60657, United States
  • Henry Ford Hosp
    Detroit, Michigan 48202, United States
  • Washington Univ
    St Louis, Missouri 63108, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Saint Vincent's Hosp and Med Ctr
    New York, New York 10011, United States
  • New York Univ Med Ctr
    New York, New York 10016, United States
  • Saint Luke's - Roosevelt Hosp Ctr
    New York, New York 10023, United States
  • Graduate Hosp / Tuttleman Cancer Ctr
    Philadelphia, Pennsylvania 19146, United States
  • Comprehensive Care Ctr
    Dallas, Texas 75235, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
07

References and documents

Publications

  • Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. doi: 10.1200/JCO.1996.14.8.2353. PubMed 8708728 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002318
Lead sponsor
Sequus Pharmaceuticals
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxorubicin · Bleomycin · Vincristine

Start the discussion